中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2015年
5期
1187-1189
,共3页
何广宁%凌晓辉%江福能%钟惟德
何廣寧%凌曉輝%江福能%鐘惟德
하엄저%릉효휘%강복능%종유덕
前列腺癌%丝氨酸/精氨酸富集剪接因子l%复发
前列腺癌%絲氨痠/精氨痠富集剪接因子l%複髮
전렬선암%사안산/정안산부집전접인자l%복발
Prostate cancer%Serine/arginine-rich splicing factor 1%Recurrence
目的 探讨丝氨酸/精氨酸富集剪接因子1(ASF/SF2)在前列腺癌的作用及其可能参与的致癌分子机制.方法 免疫组织化学法检测102例前列腺癌患者及20例前列腺良性组织ASF/SF2的表达水平.x2检验分析ASF/SF2表达同前列腺癌患者临床病理特征的相关性.Kaplan-Meier及Cox多因素模型检测ASF/SF2表达同前列腺癌生化复发的关系.结果 ASF/SF2在前列腺癌组中阳性率为51.0％ (52/102),在前列腺良性组织的阳性率为20.0％(4/20),两者差异有统计学意义(P＜0.05).ASF/SF2表达同临床病理分期显著相关(P＜0.05),其高表达与无生化复发生存率呈显著负相关(P＜0.05),Cox多因素分析表明ASF/SF2可独立预测前列腺癌生化复发的危险度(风险比=2.943,P＜0.05).结论 ASF/SF2高表达同前列腺癌的发病进程密切相关,ASF/SF2的致癌作用也许同哺乳动物雷帕霉素靶蛋白(mTOR)通路有关.
目的 探討絲氨痠/精氨痠富集剪接因子1(ASF/SF2)在前列腺癌的作用及其可能參與的緻癌分子機製.方法 免疫組織化學法檢測102例前列腺癌患者及20例前列腺良性組織ASF/SF2的錶達水平.x2檢驗分析ASF/SF2錶達同前列腺癌患者臨床病理特徵的相關性.Kaplan-Meier及Cox多因素模型檢測ASF/SF2錶達同前列腺癌生化複髮的關繫.結果 ASF/SF2在前列腺癌組中暘性率為51.0％ (52/102),在前列腺良性組織的暘性率為20.0％(4/20),兩者差異有統計學意義(P＜0.05).ASF/SF2錶達同臨床病理分期顯著相關(P＜0.05),其高錶達與無生化複髮生存率呈顯著負相關(P＜0.05),Cox多因素分析錶明ASF/SF2可獨立預測前列腺癌生化複髮的危險度(風險比=2.943,P＜0.05).結論 ASF/SF2高錶達同前列腺癌的髮病進程密切相關,ASF/SF2的緻癌作用也許同哺乳動物雷帕黴素靶蛋白(mTOR)通路有關.
목적 탐토사안산/정안산부집전접인자1(ASF/SF2)재전렬선암적작용급기가능삼여적치암분자궤제.방법 면역조직화학법검측102례전렬선암환자급20례전렬선량성조직ASF/SF2적표체수평.x2검험분석ASF/SF2표체동전렬선암환자림상병리특정적상관성.Kaplan-Meier급Cox다인소모형검측ASF/SF2표체동전렬선암생화복발적관계.결과 ASF/SF2재전렬선암조중양성솔위51.0％ (52/102),재전렬선량성조직적양성솔위20.0％(4/20),량자차이유통계학의의(P＜0.05).ASF/SF2표체동림상병리분기현저상관(P＜0.05),기고표체여무생화복발생존솔정현저부상관(P＜0.05),Cox다인소분석표명ASF/SF2가독립예측전렬선암생화복발적위험도(풍험비=2.943,P＜0.05).결론 ASF/SF2고표체동전렬선암적발병진정밀절상관,ASF/SF2적치암작용야허동포유동물뢰파매소파단백(mTOR)통로유관.
Objective Serine/arginine-rich splicing factor 1 (ASF/SF2,also known as SRSF1)is an oncogenic splicing factor in various malignancies.The aim of this study is to investigate the expression of ASF/SF2,and its clinicalpathological significance in prostate cancer (PCa).Methods Immunohistochmistry was conducted to analyze the expression of ASF/SF2 in 103 PCa samples and 20 benign prostate samples.The associations of ASF/SF2 expression with clinicopathological features and prognosis in PCa patients were analyzed by various statistical methods,such as chi-square test,Kaplan-Meier method and Log-rank test.Results The positive rate of ASF/SF2 was 51.0％ (52/102) in prostate cancer group,and 20.0％ (5/20) in benign group (P ＜ 0.05).In addition,ASF/SF2 expression in PCa tissues was significantly associated with pathological stage (P ＜ 0.05).Moreover,Kaplan-Meier survival analysis showed that the higher expression of ASF/SF2 was correlated with shorter biochemical recurrence-free survival (P ＜ 0.05).The multivariate analysis revealed that ASF/SF2 was an independent prognostic predictor for biochemical recurrence-free survival in patients with PCa (Hazard ratio =2.943,P ＜ 0.05).Conclusion Our study demonstrates the overexpression of ASF/SF2 is associated with PCa progression,and it may serve as potential therapeutic target.Further study is needed to identify the potential link between ASF/SF2 and mammalian target of rapamycin (mTOR) pathway in PCa.
